National Institute for Health and Care Research (NIHR) has announced the expansion of its Translational Research Collaboration (TRC) portfolio with the launch of a dedicated initiative for Parkinson’s disease, marking its eighth such collaboration. The move is aimed at addressing critical gaps in research and accelerating the development of new treatments and diagnostics for the condition.

Parkinson’s disease, which affects more than 166,000 people in the UK, remains a complex neurodegenerative disorder with significant unmet research needs, particularly in experimental medicine and early-stage clinical trials. Progress has often been hindered by fragmented efforts across basic science, translational research and clinical development.

The newly established NIHR Parkinson’s Disease TRC (PD-TRC) seeks to bridge these gaps by bringing together leading academic institutions, NHS centres and research infrastructure across the country. The initiative will focus on speeding up the translation of scientific discoveries into clinical applications, including disease-modifying therapies and precision diagnostics.

The collaboration will coordinate 16 centres of excellence, including eight NIHR Biomedical Research Centres and will actively engage with industry and charity partners to enhance research access and reduce inequalities across regions. It will also prioritise patient-centred research and embed patient and public involvement throughout its programmes.

The PD-TRC is led by Oliver Bandmann of the NIHR Sheffield Biomedical Research Centre, alongside Camille Carroll of the NIHR Newcastle BRC and Alistair Noyce from Queen Mary University of London.

Funding support comes from NIHR and key charity partners, including Cure Parkinson’s, Multiple System Atrophy Trust, Parkinson’s UK and PSP Association.

The collaboration will operate through four core workstreams: clinical cohorts, stratification and outcome measures, experimental therapies and capacity building. Together, these focus areas aim to strengthen research infrastructure, improve trial readiness and accelerate the delivery of new treatments to patients.

By fostering cross-sector collaboration and integrating expertise across the research ecosystem, the PD-TRC is expected to play a key role in advancing innovation and improving outcomes for people living with Parkinson’s and related neurological conditions.